Page last updated: 2024-11-04

vorinostat and Viremia

vorinostat has been researched along with Viremia in 6 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Viremia: The presence of viruses in the blood.

Research Excerpts

ExcerptRelevanceReference
"Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0."3.11Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Gay, CL1
James, KS1
Tuyishime, M1
Falcinelli, SD1
Joseph, SB1
Moeser, MJ1
Allard, B1
Kirchherr, JL1
Clohosey, M1
Raines, SLM1
Montefiori, DC1
Shen, X1
Gorelick, RJ1
Gama, L1
McDermott, AB1
Koup, RA1
Mascola, JR1
Floris-Moore, M1
Kuruc, JD2
Ferrari, G1
Eron, JJ2
Archin, NM2
Margolis, DM2
Scully, EP1
Aga, E1
Tsibris, A1
Archin, N1
Starr, K1
Ma, Q1
Morse, GD1
Squires, KE1
Howell, BJ1
Wu, G1
Hosey, L1
Sieg, SF1
Ehui, L1
Giguel, F1
Coxen, K1
Dobrowolski, C1
Gandhi, M1
Deeks, S1
Chomont, N1
Connick, E1
Godfrey, C1
Karn, J1
Kuritzkes, DR1
Bosch, RJ3
Gandhi, RT1
Cillo, AR1
Sobolewski, MD1
Fyne, E1
Piatak, M2
Coffin, JM2
Mellors, JW1
Ling, B1
Rogers, L1
Johnson, AM1
Russell-Lodrigue, K1
Hazuda, DJ2
Lifson, JD1
Veazey, RS1
Barton, K1
Hiener, B1
Winckelmann, A1
Rasmussen, TA1
Shao, W1
Byth, K1
Lanfear, R1
Solomon, A1
McMahon, J1
Harrington, S1
Buzon, M1
Lichterfeld, M1
Denton, PW1
Olesen, R1
Østergaard, L1
Tolstrup, M1
Lewin, SR1
Søgaard, OS1
Palmer, S1
Liberty, AL1
Kashuba, AD1
Choudhary, SK1
Crooks, AM1
Parker, DC1
Anderson, EM1
Kearney, MF1
Strain, MC1
Richman, DD1
Hudgens, MG1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)[NCT03803605]Phase 115 participants (Actual)Interventional2019-02-12Completed
Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834]Phase 231 participants (Actual)Interventional2018-04-26Active, not recruiting
Investigation of the Impact of Inducible, Replication-competent Latent HIV-1 as an Impediment to HIV/AIDS Cure in the Context of Sustained Viral Suppression[NCT04938518]222 participants (Anticipated)Observational [Patient Registry]2019-05-01Recruiting
Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV[NCT03692611]280 participants (Actual)Interventional2019-08-14Active, not recruiting
A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915]Phase 1/Phase 215 participants (Actual)Interventional2015-01-31Completed
IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection[NCT02042248]Phase 16 participants (Actual)Interventional2014-03-31Completed
Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection[NCT02071095]Phase 1/Phase 215 participants (Actual)Interventional2014-04-30Completed
IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chr[NCT02208167]Phase 16 participants (Actual)Interventional2015-04-07Completed
A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy[NCT01319383]Phase 1/Phase 225 participants (Actual)Interventional2011-02-28Completed
Research In Viral Eradication of HIV Reservoirs[NCT02336074]Phase 260 participants (Actual)Interventional2015-11-27Completed
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]Phase 16 participants (Actual)Interventional2016-03-31Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017 was used to measure safety where Grade 3 is defined as severe and Grade 4 is defined as potentially life-threatening. Treatment-Related AEs assessments are considered related to study product as possible, probable, or definite as defined in the protocol. (NCT03803605)
Timeframe: First day of study treatment through end of study, a total of approximately 36 weeks

Interventionpercentage of participants (Number)
VRC07-523LS + Vorinostat (VOR)0

Change From Baseline in Cell-associated HIV-1 RNA in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Interventionlog10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat0.06
Arm B: Vorinostat Alone0.17

Change From Baseline in Total HIV-1 DNA Levels in CD4+ T Cells

Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38

Interventionlog10 copies/million CD4 cells (Mean)
Arm A: Tamoxifen + Vorinostat0
Arm B: Vorinostat Alone-0.04

Proportion of Participants With New Grade 3 or Greater Adverse Events

Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65

Interventionproportion of participants (Number)
Arm A: Tamoxifen + Vorinostat0
Arm B: Vorinostat Alone0

Number of Participants With HIV-1 RNA Levels (Measured by Single Copy Assay) Greater or Equal to the Lower Limit of Quantification

Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65

,
InterventionParticipants (Count of Participants)
Pre-entry SCA >= LOQEntry SCA >=LOQDay 28 SCA >=LOQDay 35 SCA >=LOQDay 38 SCA >=LOQDay 45 SCA >=LOQDay 65 SCA >=LOQ
Arm A: Tamoxifen + Vorinostat10911117910
Arm B: Vorinostat Alone6345545

CD8 CD38 (Mean of Fluorescence)

the CD38-activation marker on CD8 T-cells (CD8/CD38). (NCT02071095)
Timeframe: Day 8

Interventionmean fluorescent intensity (MFI) (Mean)
Arm A: Poly-ICLC8.69
Arm B: Normal Saline2.35

NK Cell Number

Natural killer cells or NK cells are part of the innate immune defense against infection and cancer. (NCT02071095)
Timeframe: at 48 weeks

Interventioncells/µL (Mean)
Arm A: Poly-ICLC20.68
Arm B: Normal Saline19.41

Number Participants With Adverse Events

Safety measured by number of participants with adverse events. (NCT02071095)
Timeframe: Up to 48 weeks

InterventionParticipants (Count of Participants)
Arm A: Poly-ICLC11
Arm B: Normal Saline3

Percent Change in CD4+ Tcell-associated HIV-1 RNA as Compared to Baseline

CD4+ Tcell-associated HIV-1 RNA to determine whether Poly-ICLC disrupts viral latency in HIV-1-infected individuals on anti-retroviral therapy.Viral transcription assessed by monitoring cell associated HIV-1 RNA. Percent change compared to baseline. (NCT02071095)
Timeframe: Baseline, Day 2, Day 4, Day 8, Day 28

,
Interventionpercent change (Mean)
Day 2Day 4Day 8Day 28
Arm A: Poly-ICLC102.8134.8161.0199.6
Arm B: Normal Saline186.3254.766.33126.7

Plasma Interferon-gamma-inducible Protein-10 (IP-10) Level

One of the biomarkers of cellular immune activation and exhaustion quantified by flow cytometry. Normal range is 7.8-500 pg/ml. (NCT02071095)
Timeframe: Day 2 and Day 4

,
Interventionpg/ml (Mean)
Day 2Day 4
Arm A: Poly-ICLC381.43450.51
Arm B: Normal Saline100.65139.39

Number of Participants Developing Cancer Within 5 Years Following >/= 8 Vorinostat Dose Exposures

Development of a new cancer within the 5 years of taking their last dose of VOR 400 mg PO.All participants receiving one or more doses of VOR 400 mg PO in any and all Arms of the study. Pre-specified to be reported as one group. (NCT01319383)
Timeframe: From last dose Vorinostat to 5 years afterwards

InterventionParticipants (Count of Participants)
1/Single and Multiple Dose, Step 30
2/Interval Doses (Multiple) Step 40

Number of Participants Exhibiting an in Vivo Resting CD4+ T Cell- Associated HIV RNA (RCVL) Increase After Receiving a Single Dose of VOR 400 mg PO

Participants in Arm 1 and 2 were analyzed in Step 2 for an in vivo increase in resting CD4+ T cell- associated HIV RNA (RCVL) after administration of a single dose of VOR 400 mg PO (NCT01319383)
Timeframe: Arm1: Baseline, Visit 5 and Arm 2: Baseline and Visit 3

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Step 2, Visit 58
2/Interval Dosing, Visit 34

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Each of Two Multiple Dose Cycles (11 Doses/Cycle)

Participants in Arm 1, Step 3 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after 11 doses of VOR 400 mg PO. This cycle was repeated after a 5 - 8 week rest period for a 2nd series and measurement. (NCT01319383)
Timeframe: Baseline, Visit 18, Visit 29

InterventionParticipants (Count of Participants)
Arm 1 - Single and Multiple Dose, Step 30

Number of Participants Exhibiting an in Vivo Resting CD4+ T-cell-associated HIV RNA (Rc-RNA) Increase Following Multiple (n = 10) Interval Doses

Participants in Arm 2, Step 4 were analyzed for an in vivo increase in the resting CD4+ T cell- associated HIV RNA (RCVL) after administration of 10 doses of VOR 400 mg PO, given 72 hours apart. (NCT01319383)
Timeframe: Baseline, Visit 9

InterventionParticipants (Count of Participants)
Interval Doses (Multiple) Step 43

Number of Participants With a Significant in Vivo Response in Resting Cell Infection (RCI) and HIV RNA After Paired Doses

Induction of significant in vivo RCI and RCLV response after 2 doses of VOR 400 mg PO administered 48 hours apart or 72 hours apart (NCT01319383)
Timeframe: Baseline, Visit 6

InterventionParticipants (Count of Participants)
Interval Dosing , Step 3 (48 hr Interval)0
Interval Dosing, Step 3 (72 Hour Interval)6

Number of Participants With Confirmed Hematologic Toxicity >/= Grade 2 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

Number of Participants With Confirmed Non-hematologic Toxicity >/= Grade 3 and Related to VOR Per Division of AIDS (DAIDS) Grading Table

DAIDS Grading Table- Grade 1- mild, Grade 2- moderate; Grade 3- severe Grade 4- potentially life-threatening. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 24 hrs following single dose and 1 week after last of multiple dose sequence

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

Number of Participants With Measurable Changes in Plasma HIV-1 RNA

Assess for detectible HIV-1 RNA > 150 copies/mL, confirmed by repeat evaluation, following VOR dose. By standard assay and single copy assay. Pre specified to combine all participants into one arm. (NCT01319383)
Timeframe: 1 week after last VOR dose

InterventionParticipants (Count of Participants)
1/Single & Multiple Dose, Steps 2 and 30
2/Interval Dosing, Steps 2, 3 and 40

Histone H4 Acetylation

Histone H4 acetylation using a H4K5/8/12/16 immunoassay with thawed PBMC derived cell lysates added to an ELISA using anti-H4 monoclonal antibody (NCT02336074)
Timeframe: 12 weeks

InterventionFold increase pre to post vorinostat (Mean)
Intervention (Arm B - ART + Vaccines + Vorinostat)3.19

Quantitative Viral Outgrowth

Number of Participants with undetectable quantitative viral outgrowth (NCT02336074)
Timeframe: At week 16

InterventionParticipants with undetectable outgrowth (Number)
Control (Arm A - ART Only)12
Intervention (Arm B - ART + Vaccines + Vorinostat)6

Total HIV DNA From CD4 T-cells

The average of two measures taken at post-randomisation week 16 and 18 (NCT02336074)
Timeframe: Averaged across post-randomisation week 16 and 18

InterventionHIV-DNA copies/mill CD4+ T cells (log10) (Mean)
Control (Arm A - ART Only)2.95
Intervention (Arm B - ART + Vaccines + Vorinostat)3.06

Viral Inhibition

"CD8+ T cell antiviral suppressive activity was expressed as percentage elimination and determined as follows: [(fraction of p24+ cells in CD4+ T cells cultured alone) - (fraction of p24 + in CD4+ T cells cultured with CD8+ cells)]/(fraction of p24+ cells in CD4+ T cells cultured alone) × 100.~Viral inhibition Assay" (NCT02336074)
Timeframe: 12 weeks

InterventionPercentage elimination (Mean)
Control (Arm A - ART Only)-18.25
Intervention (Arm B - ART + Vaccines + Vorinostat)1.50

CD8+ T-cell Responses

Percentage of CD8+ CD107a+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD8+ CD107a+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0520.062
Intervention (Arm B - ART + Vaccines + Vorinostat)0.1940.263

Percentage of CD4+ CD154+ IFNγ+ T Cells

Percentage of CD4+ CD154+ IFNγ+ T cells , assessed using an optimized and qualified flow cytometry panel. (NCT02336074)
Timeframe: 12 weeks

,
Intervention% cells CD4+ CD154+ IFNγ+ (Median)
Post randomisation week 9Post randomisation week 12
Control (Arm A - ART Only)0.0060.006
Intervention (Arm B - ART + Vaccines + Vorinostat)0.0970.109

Trials

2 trials available for vorinostat and Viremia

ArticleYear
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8

    Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female

2022
Broad activation of latent HIV-1 in vivo.
    Nature communications, 2016, 09-08, Volume: 7

    Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Administration Schedule; HIV In

2016

Other Studies

4 other studies available for vorinostat and Viremia

ArticleYear
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
    The Journal of infectious diseases, 2022, 03-02, Volume: 225, Issue:5

    Topics: Broadly Neutralizing Antibodies; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Viremia;

2022
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, May-13, Volume: 111, Issue:19

    Topics: Adult; Aged; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Female; Gene Expression Regulation,

2014
Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques.
    PloS one, 2014, Volume: 9, Issue:7

    Topics: Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Darunavir; DNA, Viral; Drug Therapy, Co

2014
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
    Nature, 2012, Jul-25, Volume: 487, Issue:7408

    Topics: Acetylation; Anti-HIV Agents; Biomarkers; CD4-Positive T-Lymphocytes; Gene Expression Regulation, Vi

2012
chemdatabank.com